|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 17, 2018 ) Global Checkpoint Inhibitors Market was worth USD 6.08 billion in 2016 and is expected to reach USD 21.25 billion by 2021 with a CAGR of 28.4 %.
Browse full report @ https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market-2177/
Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.
Get free sample report @ https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market-2177/request-sample
Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/global-checkpoint-inhibitors-market-2177/
Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others. Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.
Geographically, market is further segmented into Asia-Pacific, Europe, Latin America, Middle east and Africa and North America. North America dominates the global market owing the relatively high clinical trials and funding available in this region. Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.
Some of the key players in the checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.
About Market Data Forecast™
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
